Search

Your search keyword '"Encephalopathy -- Drug therapy"' showing total 65 results
Start Over Descriptor "Encephalopathy -- Drug therapy" Database Gale General OneFile
65 results on '"Encephalopathy -- Drug therapy"'

1. Data on Brain Ischemia Described by Researchers at Duke Clinical Research Institute (Population Pharmacokinetics of Caffeine In Infants With Hypoxic-ischemic Encephalopathy: a Phase I, Dose-escalating Trial)

Subjects
Encephalopathy -- Drug therapy, Pharmacokinetics -- Research, Infants -- Health aspects, Caffeine -- Testing -- Properties
Abstract

2025 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Central Nervous System Diseases and Conditions - [...]

Published
2025

2. FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Protein binding, Business, News, opinion and commentary
Abstract

Wholly owned first-in-class program anticipated to enter clinical trials in first half of 2025 THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Capsida Biotherapeutics ('Capsida') today announced the U.S. Food [...]

Published
2024

3. University College Cork Reports Findings in Neonatal Encephalopathy (Retrospective Characterization of Seizure Semiology and Treatment Using Continuous Video-eeg Monitoring In Neonatal Encephalopathy In Uganda)

Subjects
Drug therapy, Reports, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Medical research -- Reports, Seizures (Medicine) -- Drug therapy, Neonatal diseases -- Drug therapy, Patient monitoring equipment -- Reports, Medicine, Experimental -- Reports, Infants (Newborn) -- Diseases -- Drug therapy
Abstract

2024 DEC 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Infant and Newborn Diseases and Conditions - Neonatal Encephalopathy [...]

Published
2024

5. Study Results from Cumming School of Medicine Broaden Understanding of Brain Ischemia (Persistent pulmonary hypertension and short-term neurological outcomes in infants with moderate to severe hypoxic ischemic encephalopathy)

Subjects
Drug therapy, Diseases, Brain, Pulmonary hypertension -- Drug therapy, Infants, Cerebral ischemia -- Drug therapy, Encephalopathy -- Drug therapy, Neonatology
Abstract

2024 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Researchers detail new data in brain ischemia. According to news reporting from Calgary, Canada, [...]

Published
2024

6. Institute for Cancer Research and Treatment (IRCCS) Researcher Details Research in Epileptic Encephalopathy (Efficacy and Safety of Pulse Intravenous Methylprednisolone in Pediatric Epileptic Encephalopathies: Timing and Networks Consideration)

Subjects
Drug therapy, Cancer treatment, Encephalopathy -- Drug therapy, Cancer -- Drug therapy, Child health, Cancer research, Pediatrics, Glucocorticoids, Methylprednisolone, Oncology, Experimental, Corticosteroids, Cancer -- Care and treatment -- Drug therapy -- Research, Children -- Health aspects
Abstract

2024 MAY 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on epileptic encephalopathy. According to news originating from Bologna, [...]

Published
2024

7. Reports from Baylor University College of Medicine Describe Recent Advances in Brain Ischemia (Clinical Exome Sequencing Uncovers Genetic Disorders In Neonates With Suspected Hypoxic-ischemic Encephalopathy: a Retrospective Analysis)

Subjects
United States. National Institute of General Medical Sciences, Baylor College of Medicine, Drug therapy, Diseases, Cerebral ischemia -- Drug therapy, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Medical research, Nervous system diseases -- Drug therapy, Medical schools, Medicine, Experimental, Medical colleges, Infants (Newborn) -- Drug therapy
Abstract

2024 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Central Nervous System Diseases and Conditions - Brain Ischemia [...]

Published
2024

8. Findings on Brain Ischemia Reported by Investigators at Michigan State University (Evaluating the Safety and Efficacy of Erythropoietin Therapy for Neonatal Hypoxic-ischemic Encephalopathy: a Systematic Review and Meta-analysis)

Subjects
Michigan State University -- Reports, Drug therapy, Analysis, Reports, Cerebral ischemia -- Drug therapy, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Medical research -- Analysis -- Reports, Nervous system diseases -- Drug therapy, Brain research -- Analysis -- Reports, Erythropoietin -- Analysis -- Reports, Medicine, Experimental -- Analysis -- Reports, Infants (Newborn) -- Drug therapy
Abstract

2024 MAR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on Central Nervous System Diseases and Conditions - Brain Ischemia are [...]

Published
2024

11. Bambino Gesu Children's Hospital Researchers Publish New Data on Progressive Myoclonic Epilepsy [Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case ...]

Subjects
Drug therapy, Diseases, Myoclonic epilepsy -- Drug therapy, Physical fitness, Metreleptin, Encephalopathy -- Drug therapy, Lipodystrophy -- Drug therapy
Abstract

2020 NOV 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on progressive myoclonic epilepsy is now available. According to [...]

Published
2020

12. Researchers at Zhejiang University School of Medicine Have Reported New Data on Dementia (TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy)

Subjects
Drug therapy, Health aspects, Physical fitness -- Health aspects, Encephalopathy -- Drug therapy, Nervous system diseases -- Drug therapy
Abstract

2020 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Neurodegenerative Diseases and Conditions - Dementia are presented in [...]

Published
2020

13. University College London (UCL) School of Pharmacy Researchers Describe Findings in Ischemia (Neuroprotective Effects of Diabetes Drugs for the Treatment of Neonatal Hypoxia-Ischemia Encephalopathy)

Subjects
Drug therapy, Analysis, Physical fitness -- Analysis, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Hypoglycemic agents -- Analysis, Type 2 diabetes -- Drug therapy, Pharmacy -- Analysis, Diabetes therapy -- Analysis, Medical research -- Analysis, Ischemia -- Drug therapy, Time, Obesity, Editors
Abstract

2020 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in ischemia. According to news reporting from London, [...]

Published
2020

14. Two South Indian children with KCNT1-related malignant migrating focal seizures of infancy - Clinical characteristics and outcome of targeted treatment with quinidine

Author

Patil, Abhijit, Vinayan, K., and Roy, Arun

Subjects
Drug therapy, Research, Dosage and administration, Health aspects, Infants -- Health aspects, Quinidine -- Dosage and administration, Encephalopathy -- Drug therapy, Neurons -- Research, Oxcarbazepine, Genes, Potassium channels, Levetiracetam, Lacosamide, Anticonvulsants, Electrocardiography, Children
Published
2019

15. Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Subjects
Stroke (Disease) -- Drug therapy, Encephalopathy -- Drug therapy, Clinical trials, Infants (Newborn) -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

WILLOWBROOK, Ill., Aug 29, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END Sovateltide is an endothelin-B receptor agonist that is neuroprotective, neurorestorative, and produces neurovascular remodeling Sovateltide marketing authorization for [...]

Published
2022

16. USA FDA Grants Fast Track Designation to ReAlta Life Sciences' Lead Compound RLS-0071 for the Treatment of Hypoxic-Ischemic Encephalopathy In Neonates

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Infants (Newborn) -- Drug therapy, Business, Business, international
Abstract

RLS-0071 is ReAlta's lead dual-action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases NORFOLK, Va. -- ReAlta [...]

Published
2022

17. New Antineoplastics Study Results Reported from University of Paris-Saclay (5-fluorouracil Rechallenge After 5-fluorouracil-induced Hyperammonemic Encephalopathy)

Subjects
Drug therapy, Research, Dosage and administration, Complications and side effects, Encephalopathy -- Drug therapy, Fluorouracil -- Research -- Dosage and administration -- Complications and side effects, Toxicity, Bevacizumab, Gastrointestinal diseases, Physical fitness, Editors
Abstract

2019 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Antineoplastics have been presented. According [...]

Published
2019

18. Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Subjects
Stroke (Disease) -- Drug therapy, Encephalopathy -- Drug therapy, Clinical trials, Infants (Newborn) -- Drug therapy, General interest, News, opinion and commentary
Abstract

WILLOWBROOK: Pharmazz, Inc. has issued the following news release: Pharmazz, Inc. ('Pharmazz'), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today announced [...]

Published
2022

19. Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Subjects
Stroke (Disease) -- Drug therapy, Encephalopathy -- Drug therapy, Drugs -- Product development -- Standards, Clinical trials, Infants (Newborn) -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

WILLOWBROOK, Ill., Feb 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- Sovateltide is an endothelin-B receptor agonist that has been shown to increase blood flow, show anti-apoptotic activity, and produce neurovascular [...]

Published
2022

20. Data from University of Texas Southwestern School of Medicine Provide New Insights into Brain Ischemia (New Horizons In Mild Hypoxic-ischemic Encephalopathy: a Standardized Algorithm To Move Past Conundrum of Care)

Subjects
Drug therapy, Algorithm, Algorithms, Cerebral ischemia -- Drug therapy, Encephalopathy -- Drug therapy, Nervous system diseases -- Drug therapy
Abstract

2022 JUL 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Central Nervous System Diseases and Conditions - Brain [...]

Published
2022

21. Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia

Author

Liu, Xun, Borooah, Manobi, Stone, Janet, Chakkarapani, Ela, and Thoresen, Marianne

Subjects
Gentamicin -- Usage, Gentamicin -- Health aspects, Gentamicin -- Complications and side effects, Encephalopathy -- Drug therapy, Encephalopathy -- Patient outcomes, Hypothermia -- Drug therapy, Hypothermia -- Physiological aspects, Infants (Newborn) -- Drug therapy, Infants (Newborn) -- Patient outcomes
Published
2009

22. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy

Author

Roka, Aniko, Melinda, Kis Tamas, Vasarhelyi, Barna, Machay, Tamas, Azzopardi, Denis, and Szabo, Miklos

Subjects
Hypothermia -- Demographic aspects, Hypothermia -- Research, Hypothermia -- Patient outcomes, Encephalopathy -- Drug therapy, Encephalopathy -- Complications and side effects, Encephalopathy -- Demographic aspects, Encephalopathy -- Research, Asphyxia neonatorum -- Patient outcomes, Asphyxia neonatorum -- Research, Morphine -- Dosage and administration, Morphine -- Complications and side effects, Morphine -- Research, Pharmacokinetics -- Research
Published
2008

23. Recent Findings from Hospital Ruber Internacional Highlight Research in Epileptic Encephalopathy (Epilepsy Genetics and Precision Medicine in Adults: A New Landscape for Developmental and Epileptic Encephalopathies)

Subjects
Drug therapy, Precision medicine, Encephalopathy -- Drug therapy, Epilepsy -- Drug therapy, Adults
Abstract

2022 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in epileptic encephalopathy. According to news reporting originating from [...]

Published
2022

24. ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, international, Law
Abstract

ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. This [...]

Published
2020

25. ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, Business, international
Abstract

RLS-0071 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that the [...]

Published
2020

26. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)

Subjects
Anticonvulsants -- Health aspects, Epilepsy in children -- Drug therapy, Encephalopathy -- Drug therapy
Abstract

The antiepileptic drug felbamate may be useful in treating patients with Lennox-Gastaut syndrome. This syndrome is a severe form of epilepsy characterized by the childhood onset of many types of seizures and progressive mental retardation. In a two-phase study, 73 patients with Lennox-Gastaut syndrome took their regular antiepileptic drugs for 28 days. In the second phase, 37 patients took felbamate in addition to their regular treatment and 36 took a placebo and their regular treatment. There was a 34% decrease of atonic seizures (that cause a fall) among patients taking felbamate compared with only a 9% decrease among patients taking placebo. The total frequency of seizures as reported by the parents dropped 19% among patients taking felbamate, but rose 4% among patients taking placebo. Furthermore, parents of patients taking felbamate gave higher quality-of-life ratings for their children than did parents of patients taking placebo. The side effects experienced were similar in both groups and not severe.

Published
1993

28. Reversible posterior leucoencephalopathy during oral treatment with methotrexate

Author

Renard, Dimitri, Westhovens, Rene, Vandenbussche, Erik, and Vandenberghe, Rik

Subjects
Encephalopathy -- Drug therapy, Methotrexate -- Dosage and administration, Health
Abstract

Byline: Dimitri Renard (1), Rene Westhovens (2), Erik Vandenbussche (1), Rik Vandenberghe (1) Author Affiliation: (1) Neurology Department, University Hospital Gasthuisberg, Leuven, Belgium (2) Department of Rheumatology, University Hospital Gasthuisberg, Leuven, Belgium Article History: Registration Date: 01/01/2004 Received Date: 20/05/2003 Accepted Date: 18/09/2003

Published
2004

29. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration -- Planning, Encephalopathy -- Drug therapy, Orphan drugs -- Planning, Insurance industry, Strategic planning (Business), Media executives, Newborn infants, Company business planning, Business, international, Law
Abstract

ReAlta Life Sciences, Inc., today announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PIC1-dPEG24 for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. There [...]

Published
2020

30. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Insurance industry, Media executives, Newborn infants, General interest, News, opinion and commentary
Abstract

NORFOLK, Va: ReAlta Life Sciences, Inc. has issued the following news release: ReAlta Life Sciences, Inc., today announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation [...]

Published
2020

31. ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Orphan drugs, Insurance industry, Media executives, Newborn infants, Diseases, Business, Business, international
Abstract

PIC1 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease NORFOLK, Va. -- ReAlta Life Sciences, Inc., today announced that U.S. [...]

Published
2020

32. Progressive multifocal leukoencephalopathy; Cidofovir therapy in three patients with underlying hematological disease

Author

Herrlinger, Ulrich, Schwarzler, Frank, Beck, Robert, Kuker, Wilhelm, Hebart, Holger, Kanz, Lothar, Dichgans, Johannes, and Weller, Michael

Subjects
Encephalopathy -- Drug therapy, Cidofovir -- Dosage and administration, Health
Abstract

Byline: Ulrich Herrlinger (1), Frank Schwarzler (1), Robert Beck (2), Wilhelm Kuker (3), Holger Hebart (4), Lothar Kanz (4), Johannes Dichgans (1), Michael Weller (1) Author Affiliation: (1) Department of Neurology, University of Tubingen, Medical School, Hoppe-Seyler-Str. 3, 72076 Tubingen, Germany. ulrich.herrlinger@uni-tuebingen.de, DE (2) Institute of Medical Virology, University of Tubingen, Tubingen, Germany, DE (3) Dept. of Neuroradiology, University of Tubingen, Tubingen, Germany, DE (4) Dept. of Haematology and Medical Oncology, University of Tubingen, Tubingen, Germany, DE Article note: Received: 12 October 2002, Accepted: 2 December 2002 Correspondence to Ulrich Herrlinger

Published
2003

33. ReAlta Life Sciences Granted EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal Encephalopathy

Subjects
United States. Food and Drug Administration, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Orphan drugs, Business, Business, international, Telecommunications industry
Abstract

ReAlta Life Sciences reported that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. According to a [...]

Published
2020

34. Recent Findings in HIV/AIDS Described by Researchers from Stellenbosch University (Recovery of HIV encephalopathy in perinatally infected children on antiretroviral therapy)

Subjects
Drug therapy, Highly active antiretroviral therapy, Encephalopathy -- Drug therapy, Child health, HIV -- Drug therapy, Medical research, Antiretroviral agents
Abstract

2020 AUG 24 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Researchers detail new data in Immune System Diseases and Conditions - HIV/AIDS. According to news [...]

Published
2020

35. Findings from Hubei University of Medicine in the Area of Diabetes Mellitus Described (A novel hippocampus metabolite signature in diabetes mellitus rat model of diabetic encephalopathy)

Subjects
Drug therapy, Reports, Brain -- Reports, Diabetes mellitus -- Drug therapy, Encephalopathy -- Drug therapy, Metabolites -- Reports, Medical research -- Reports, Finance, Editors, Diseases
Abstract

2020 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Research findings on Nutritional and Metabolic Diseases and Conditions - Diabetes Mellitus are discussed in [...]

Published
2020

36. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy

Author

Hriso, Emmanuel, Kuhn, Thomas, Masdeu, Joseph C., and Grundman, Michael

Subjects
Extrapyramidal disorders -- Causes of, Encephalopathy -- Drug therapy, AIDS (Disease) -- Complications, Antipsychotic drugs -- Adverse and side effects, Health, Psychology and mental health
Abstract

Brain disease (encephalopathy) with resulting psychiatric symptoms is commonly seen in AIDS patients. The psychiatric symptoms are usually treated with neuroleptic (antipsychotic) drugs. These drugs can cause serious side effects, including the tremors associated with parkinsonism. There are some indications that AIDS patients are more susceptible to the side effects of neuroleptic drugs than are other patients. To examine this issue further, the medical charts of 31 AIDS patients and 32 non-AIDS patients who had taken neuroleptic drugs for less than one month were reviewed. The mean drug dose (in chlorpromazine equivalents) given to AIDS patients was 301.1 mg per day and to non-AIDS patients was 679.4 mg per day. When doses were adjusted for weight, the means were 4.6 and 9.1 mg per kg of body weight per day, respectively. Each group was then divided into subgroups by those who received doses of less than 4 mg/kg/d and those who received more. There were 22 AIDS patients and seven non-AIDS patients in the group receiving less than 4 mg/kg/d. Extrapyramidal symptoms such as parkinsonism were noted for 11 of the 22 AIDS patients and for two of the seven non-AIDS patients. In the groups taking more than 4 mg/kg/d, seven of nine AIDS patients and 15 of 25 non-AIDS patients were seen to have extrapyramidal symptoms. Overall, AIDS patients were 2.4 times more likely to have such symptoms than non-AIDS patients. These results indicated that neuroleptic drugs should be used cautiously in the treatment of AIDS patients. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

37. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)

Author

Gay, Patricia E., Mecham, Guy F., Coskey, Jason S., Sadler, Toni, and Thompson, Joel A.

Subjects
Anticonvulsants -- Psychological aspects, Epilepsy in children -- Drug therapy, Encephalopathy -- Drug therapy, Psychology and mental health
Abstract

The behavioral effects of felbamate were assessed in 20 persons (ages 2 to 19 years) who were participating in a compassionate plea protocol for children with Lennox-Gastaut syndrome. Parents completed a questionnaire concerning aspects of behavioral change once all medications were in a constant regimen. Significant improvements were suggested in social functioning, intellectual functioning, motor functioning, attention and concentration, alertness, initiative, variability in performance, and memory. There was a tendency for these effects to reverse when the drug was discontinued.

Published
1995

38. OTC: Living with...M.E

Subjects
Antidepressants -- Dosage and administration, Encephalopathy -- Diagnosis, Encephalopathy -- Drug therapy, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries
Abstract

After collapsing at work, Jenny's GP prescribed antidepressants and told her to pull herself together. A year later she was diagnosed with ME Sarah Thackray ME hit the headlines recently [...]

Published
2009

39. Data on Acute Encephalopathy Discussed by Researchers at Inje University College of Medicine (Acute Encephalopathy With Biphasic Seizures and Late Reduced Diffusion Associated With Adenoviral Pneumonia)

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Pneumonia -- Drug therapy, Nervous system diseases -- Drug therapy, Seizures (Medicine) -- Drug therapy, Medical research, Central nervous system, Editors
Abstract

2019 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Current study results on Central Nervous System Diseases and Conditions - Acute Encephalopathy have [...]

Published
2019

41. 8G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2012

42. 8G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

43. 9G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

44. Data from Baylor University College of Medicine Advance Knowledge in Seizures (Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant)

Subjects
Drug therapy, Diseases, Encephalopathy -- Drug therapy, Newborn infants -- Drug therapy, Epilepsy -- Drug therapy, Seizures (Medicine) -- Drug therapy, Nervous system diseases -- Drug therapy
Abstract

2017 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on Nervous System Diseases and Conditions - Seizures is [...]

Published
2017

45. Reports Outline Liver Transpls Study Results from Institute for Cancer Research and Treatment (IRCCS) (Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease)

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Liver cancer -- Drug therapy, Cancer research, Liver transplantation
Abstract

2016 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Transplant Medicine have been published. According to news reporting originating in [...]

Published
2016

46. Data on Human Genetics Reported by Researchers at Institute for Cancer Research and Treatment (IRCCS) (Myoclonic Encephalopathy in 9q33-q34 Deletion Encompassing STXBP1 and SPTAN1)

Subjects
Drug therapy, Genetic research, Cancer genetics -- Drug therapy, Encephalopathy -- Drug therapy, Cancer -- Drug therapy, Cancer research
Abstract

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on Genetics are presented in a new report. According to news reporting out of Foggia, Italy, [...]

Published
2015

47. 8G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

48. 8G: hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

49. 8G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

50. 8G Hepatic encephalopathy

Subjects
Drug therapy, Encephalopathy -- Drug therapy, Lactulose
Abstract

Lactulose solution (various) Rx Colonic acidifier. Lactulose 10g/15mL; soln; for oral or rectal administration. Indications: Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Adults: [...]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results